NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Emmecell

Emmecell

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://www.emmecell.com/

Last Round

Strategic

Jun 16, 2026

Total Funding Raised

$46M

Company Overview

Emmecell is a biotechnology company that develops cell-based therapies for the treatment of eye diseases using its proprietary Magnetic Cell Delivery (MCD) nanoparticle platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

cell therapymagnetic cell deliverycorneal edemaophthalmic therapiesclinical stage biotechregenerative medicineMCD platformnanoparticle deliverycorneal transplant alternativecGMP manufacturingcell therapy CDMOophthalmologygeographic atrophyglaucoma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Emmecell Comparables

Compare Emmecell with similar companies based on industry and business-model similarity.

Emmecell comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Trefoil Therapeutics
81%
ActualEyes, Inc.
80%
Cellusion Inc.
80%

Emmecell Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJun 16, 2026
Series AJan 19, 2026

Key People

Founding team and executive leadership

Ramin Valian

Chief Executive Officer

Executive Team

Cyril Allouche

Chief Financial Officer & Treasurer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 23, 2026

    Monthly visitors grew 71% MoM, reaching 2.2K.

  • Nov 6, 2025

    Monthly visitors increased 80% MoM.

Emmecell Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Emmecell Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Emmecell's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range12
Year Founded2012
Last FundingJun 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.